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FIGURE 3. Our general approach to mechanical ventricular assistance.
ECMO, Extracorporeal oxygenation; BTT, bridge to transplantation;
VAD, ventricular assist device; P-VAD, paracorporeal ventricular assist de-
vice; I-VAD, implantable ventricular assist device; BSA, body surface area.
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Dprime and elimination of bridges, connectors, and diamonds
has reduced some of the morbidity experienced with the
earlier circuit.
In summary, we have found it helpful to have a variety of
mechanical ventricular assistance available so as to tailor
the device strategy to the patient. Although we have no
firm algorithm in this setting, our general approach is out-
lined in Figure 3. Our initial indication for ECMO use per-
tains to the need for oxygenation, and we favor VAD
support where feasible, given (1) the substantial advantages
of potential extubation and ambulation/rehabilitation and
(2) the disadvantages of having an oxygenator in line (eg,
activation of inflammation, increased requirement for anti-
coagulation, and limited durability). This inclination is in
keeping with other reports demonstrating superior survival
in patients supported with VAD rather than ECMO.18,19 The
selection of VAD devices is directed mostly by size and the
need for univentricular or biventricular support; however,
the optimal strategy to support patients in the ‘‘gray
zone’’ of size (15-35 kg) remains somewhat patient-
specific. For those patients in whom neurologic status is
in question, we have used a ‘‘bridge to decision’’ approach,
initially using a temporary device or ECMO until a more de-
finitive neurologic prognosis can be determined, at which
point transition to a longer-term device can take place. Al-
though we have favored using ECMO to support patients
with complex congenital heart disease in the past, we would
imagine them to be VAD candidates (following this algo-
rithm by size) in many circumstances.
Mechanical circulatory support using a variety of devices
is a highly effective means of both bridging patients to
transplantation and supporting patients after transplantation
during hemodynamic crises. The more widespread avail-
ability of smaller and potentially implantable devices for
children will only serve to improve these strategies, while
potentially affecting favorably the substantial morbidity
related to anticoagulation in the smallest patients.The Journal of Thoracic and CaReferences
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Dr J. William Gaynor (Philadelphia, Pa). I congratulate
Dr Chen and his co–investigators on a very interesting presentation
and thank them for allowing me to review the manuscript.rdiovascular Surgery c Volume 143, Number 2 349
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DThis is an important subject. As we have all seen, increasing
numbers of children are listed for cardiac transplantation. In light
of the nonincreasing donor pool, waiting times continue to in-
crease and the potential loss of patients on the waiting list is a sig-
nificant problem. The findings of this study are very similar to our
findings in a similar sized patient cohort, that overall survival to
transplant is excellent and that survival after transplant from
a VAD is equivalent to that of patients undergoing transplantation
without a VAD. I think this is a very effective technique.
We also see the same problems with thrombosis and hemor-
rhage, particularly in the very small devices and in the very small
EXCOR devices, so our overall outcomes are very similar. We do
have some management differences, and that is going to be the
focus of my question.
We rarely need to use BiVAD support. We have a very similar
patient mix and primarily cardiomyopathies, and in 33 patients
we have only needed to use BiVAD support twice. We place an
LVAD in the operating room, attempt to wean from bypass, usually
with inhaled nitric oxide, and if we do not require excessive inotro-
pic support, we have been very successful and continue with that.
What are your criteria for a BiVAD? How do you decide? Are
you continuing to use a lot of BiVAD support?
Dr Chen. Thank you. Excellent question. Our management is
very similar to yours insofar as we would always like to try to
get away with one pump only, if only because more pumps just
mean more potential for complications.
Earlier in our series we were seeing more children who were re-
ally in shock and going to the operating room while undergoing
chest compressions. Those children are the least likely to come
away with a single-sided device only. As we have gotten more
comfortable and more aggressive, the likelihood of catching pa-
tients earlier who will have reasonable right ventricular function
is good.
I also think that in the later part of this experiencewewere using
many fewer pulsatile, fill-to-empty left ventricular inflow devices.
None of these, the centrifugal or axial flow devices, decompresses
the ventricle quite as much and probably causes as much septal
shift. So more recently I am hoping, as you point out, that we
will be using fewer and fewer BiVADS and more and more LVADs
as long we can effectively manage some right heart failure
medically.
DrGaynor.You also mentioned that you switched to atrial can-
nulation. We have continued to use primarily apical cannulation
except in patients with restricted physiology, and we believe that
we get better decompression of the ventricle. We have not seenma-
jor problems with the septal shifting. When would you use atrial
cannulation now, if ever?
Dr Chen. That is a relatively new finding for us. It has been
prompted a little bit by the hemorrhage/thrombosis component,
which is that putting in the 2 atrial cannulas is very easy off
pump. With this strategy, you can get away with half-dose heparin
and the bleeding is trivial in the operating room.
The disadvantage, of course, is that the decompression of the
ventricle is less effective.Also, there is a possibility that if the aortic
valve does not open, these children will have stasis in the left ven-
tricle and later clot if we do not start fairly aggressive anticoagula-
tion quickly enough. Some of the devices, of course, cannot be
inserted atrially, but it is a much simpler approach if it is possible.350 The Journal of Thoracic and Cardiovascular SurgDr Gaynor. I have 1 final question from the manuscript, which
you did not address in the presentation, concerning the manage-
ment of patients who have intracardiac shunts. We always do
a very careful search for intracardiac shunts, and we have enclosed
them if we know we have them. We had 1 patient with an undiag-
nosed patent foramen ovale who was significantly desaturated
when he came off LVAD support. Youmentioned in themanuscript
that with this off–pump technique you will leave patients with
intracardiac shunts and have not seen that problem. Could you
expand on that?
Dr Chen. It was really more out of good luck, I think, than any-
thing. Regarding the intracardiac shunt component, a lot of these
newer continuous flow devices do not decompress the ventricle
enough that we get as much right-to-left shunting as we used to
with their fill-to-empty predecessors. I was very concerned in 1 pa-
tient, the smallest patient here, who had a BiVAD and multiple
ventricular septal defects, that it was going to be hard to control
the degree of shunting. However, it ended up not being so much
of a problem. Atrial cannulation can be tricky with regard to atrial
communications, though, and I suspect those probably still need to
be closed.
Dr Gaynor. This answer brings up a further question. Most of
our cases are bridged to transplant; we almost never bridge to re-
covery. We are always concerned that children frequently come in
with high left atrial pressures and pulmonary edema, and we are
concerned about dropping that left atrial pressure to improve the
lungs. If you are using a device that does not decompress, will
the atrial cannulation alone drop the left atrial pressure sufficiently
to allow the lungs to recover?
Dr Chen. I do not know the answer to that. I would assume that
the atrial cannulation probably will. I certainly do not think ECMO
does though. It has definitely been our policy that if you are bridg-
ing to transplant with ECMO and you suspect high atrial pressures,
you have to go to the catheterization laboratory for a septostomy at
the time of instituting ECMO support, or very soon thereafter.
Dr Carl L. Backer (Chicago, Ill). For the patients whom you
are supporting with ECMO, what is your decision tree for where
to do the cannulation—neck, femoral, or median sternotomy?
We recently had an older child who came in with myocarditis.
I put her on ECMO through the chest and she came off ECMO
and went home after she was treated. The advantage of this in
the older child is that there are no femoral or neck vessel compli-
cations. When these patients come in, it seems that there is always
some discussion about where to do the ECMO cannulation. What
is your strategy?
Dr Chen. For the smaller children—and our cutoff ends up be-
ing about 2 years—we go on through the neck. The hard group is
that between about 5 kg and about 15 kg, because we have had
a fair number of groin complications with that size range, even
with the T’d-off sidearm that goes through the dorsalis pedis.
When the patients get to be older and bigger, you can easily go
with 2 venous cannulas, neck and groin, and femoral artery. It is
just that middle group, I think, that is probably the right group to
be having a sternotomy because it is much simpler and the vascular
complications are substantial.
Dr Hajime Ichikawa (Osaka, Japan). I am really interested in
your atrial cannula. We used to use an atrial cannula with Japanese
Toyobo LVADs and we had a lot of problem with thrombosis.ery c February 2012
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DDo you change the anticoagulant regimen when using an atrial
cannula?
Dr Chen.May I ask a question? Is the thrombosis in the pump
or in the ventricle?
Dr Ichikawa. In the ventricle.
Dr Chen.We have worried a lot about thrombosis in the ventri-
cle. We definitely run PTTs pretty high on all of these children; es-
pecially in the smaller children, we will run the PTTs well above
100. This is not necessarily based on the flow in the ventricle
and so forth, but just as a general policy.
Dr Shunji Sano (Okayama, Japan).When I look at your table,
the average duration is relatively short compared with the Toyobo
device. The Toyobo device is completely different, almost 1 year.
But most of these patients are relatively large children. So
even with a Toyobo device, you use the adult size device. Why
is the duration long and why was there only 1 episode of
thromboembolism?
When I look at the small child, in this case comprising only 3
patients—1 with a Berlin Heart, 1 with the PediMag, and 1 with
the Abiomed—they weighed less than 10 kg. The longest duration
was 17 days. How long do you think it is safe to wait for transplantThe Journal of Thoracic and Ca
Hwith these 3 devices in very small babies weighing less than 10
kg—1 month or 6 months or 1 year?
Dr Chen. The answer as to why that waiting time was so long
for the Toyobo patients is that, as you know, children in Japan have
to wait a fair amount of time for a potential donor. Each US pro-
gram can only have 5% of their transplant volume as comprised
of foreign national candidates, so sometimes these international
children have to wait for the calendar year to turn over before
we can accept them. There can be quite a bit of time for waiting
and it takes time to raise money and so forth.
Early in our experience we used the adult CentriMag circuit
rather than the PediMag; that is a 3/8–inch connection all the
way around. It is actually a fairly large priming volume. A lot of
children who were just over 10 kg in this group, about 11 to 13
kg, would form a lot of early thrombus in the tubing, and so I started
adapting to exchanging the tubing routinely at 2 weeks. We carried
some of those patients up to about 6 weeks.
I do worry, though, when we put the smallest children on de-
vices. We really try to get the transplant done as quickly as possi-
ble. The good news is that most of them can receive transplants
across ABO blood groups because of their age.rdiovascular Surgery c Volume 143, Number 2 351
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